LI Jia-yi, XING Bing*
| de Filette J, Andreescu CE, Cools F, et al. A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors[J]. Horm Metab Res, 2019, 51: 145-156.
Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis[J]. JAMA Oncol, 2018, 4: 173-182.
Baxi S, Yang A, Gennarelli RL, et al. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis[J]. BMJ, 2018, 360: k793.doi:10.1136/bmj.k793.
Guerrero E, Johnson DB, Bachelot A, et al. Immune checkpoint inhibitor-associated hypophysitis-World Health Organisation VigiBase report analysis[J]. Eur J Cancer, 2019, 113: 10-13.
Faje A. Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights[J]. Pituitary, 2016, 19: 82-92.
Faje AT, Sullivan R, Lawrence D, et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma[J]. J Clin Endocrinol Metab, 2014, 99: 4078-4085.
Caturegli P, Di Dalmazi G, Lombardi M, et al. Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series[J]. Am J Pathol, 2016, 186: 3225-3235.
Iwama S, De Remigis A, Callahan MK, et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody[J]. Sci Transl Med, 2014, 6:230ra45.doi:10.1126/scitranslmed. 3008002.
Bellastella G, Maiorino MI, Bizzarro A, et al. Revisita-tion of autoimmune hypophysitis: knowledge and uncertainties on pathophysiological and clinical aspects[J]. Pituitary, 2016, 19: 625-642.
Lin CH, Chen KH, Chen KY, et al. Immune checkpoint inhibitor therapy-induced hypophysitis approximately a case series of Taiwanese patients[J]. J Formos Med Assoc, 2019, 118: 524-529.
Iglesias P. Cancer immunotherapy-induced endocrinopathies: clinical behavior and therapeutic approach[J]. Eur J Intern Med, 2018, 47: 6-13.
Brahmer JR, Lacchetti C, and Thompson JA. Manage-ment of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline summary[J]. J Oncol Pract, 2018, 14: 247-249.
Nallapaneni NN, Mourya R, Bhatt VR, et al. Ipilimu-mab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash[J]. J Natl Compr Canc Netw, 2014, 12: 1077-1081.
Wachsmann JW, Ganti R, Peng F. Immune-mediated disease in ipilimumab immunotherapy of melanoma with FDG PET-CT[J]. Acad Radiol, 2017, 24: 111-115.
van der Hiel B, Blank CU, Haanen JB, et al. Detection of early onset of hypophysitis by (18)F-FDG PET-CT in a patient with advanced stage melanoma treated with ipilimumab[J]. Clin Nucl Med, 2013, 38: e182-184.
Byun DJ, Wolchok JD, Rosenberg LM, et al. Cancer immunotherapy-immune checkpoint blockade and associated endocrinopathies[J]. Nat Rev Endocrinol, 2017, 13: 195-207.
Joshi MN, Whitelaw BC, and Carroll PV. Mechanisms in endocrinology: hypophysitis: diagnosis and treatment[J]. Eur J Endocrinol, 2018, 179: R151-R163.
Albarel F, Gaudy C, Castinetti F, et al. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma[J]. Eur J Endocrinol, 2015, 172: 195-204.
Corsello SM, Barnabei A, Marchetti P, et al. Endocrine side effects induced by immune checkpoint inhibitors[J]. J Clin Endocrinol Metab, 2013, 98: 1361-1375.
Faje AT, Lawrence D, Flaherty K, et al. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma[J]. Cancer, 2018, 124: 3706-3714.
Min L, Hodi FS, Giobbie-Hurder A, et al. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study[J]. Clin Cancer Res, 2015, 21: 749-755.
|||GAN Zi-ying, TANG Hui. Research progress of oncolytic virus combined with PD-1/PD-L1 inhibitors [J]. Basic & Clinical Medicine, 2022, 42(4): 651-655.|
|||ZHANG Ruo-xi, HAN Bing. Progress of immune checkpoint inhibitors for the treatment of myelodysplastic syndrome [J]. Basic & Clinical Medicine, 2021, 41(8): 1210-1215.|